dotMD.com
Join Community
📖Clinical Research Library Talk in Gut, Labs & Supplements Space 711+ Logs • Free →🧮Lab Calculator ↓
Reading this clinical breakthrough? See how real patients are applying these numbers in real life. Compare real-world patient outcomes, lab numbers, and doctor visit tips—100% free with a private @handle and zero login wall.
Click to Ask a Question or Post Your Experience ▾
Post to Gut, Labs & Supplements Space (15 Seconds • No Account or Email Required)
Or read existing discussions in Gut, Labs & Supplements Space →
★ Breakthrough Medical Research • 15 Landmark Multi-Trial Guides • 6,255 Indexed Studies

Patient Literacy, FDA Pharmacokinetics & Generic Drug Quality — Clinical Trial Breakdowns & PubMed Evidence

Evidence-audited guides decoding FDA food-effect bioavailability studies ("Take With Food"), FDA Orange Book 80%–125% generic bioequivalence (3.5% mean AUC difference across 2,070 human studies), and AHRQ 15-minute doctor visit question checklists. Explore 187 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.

★ #1 Lead Breakthrough Study • NEJM SURMOUNT-1 (176 Weeks) N = 1,032 Adults • p < 0.001

Once-Weekly Tirzepatide Cuts Type 2 Diabetes Progression by 94% Over 3 Years—With a 22.9% Sustained Weight Reduction

The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).

Read the Full Breakthrough Breakdown → Jump to All 15 Landmark Breakthroughs ↓
Two biomedical scientists in white lab coats inside a sunlit medical research laboratory pipetting clinical assay samples and reviewing trial results
Inside the Clinical Evidence Lab: Our research desk audits 6,255 human trials from NEJM, The Lancet, JAMA, and NCBI PubMed—reporting true Absolute Risk Reduction (ARR) and sample sizes (N) without pharma spin.
Reset
1. Major Clinical Breakthroughs & Deep-Dive Study Breakdowns (3 Guides)

Patient Literacy & FDA Rules: Landmark Study Breakdowns

Plain-English breakdowns of the most important human trials—showing actual benefit percentages (ARR/NNT), dosing rules, and who should be careful.

Clinician Time-Motion & Shared Decision-Making Trials N = 4,820 Clinical Encounters

7 Questions to Bring to Your Next Doctor Visit (So You Never Leave a 15-Minute Appointment Confused)

Bottom-Line Trial Result: Median Time Before Clinician Interruption: 11 Seconds (36% Solicited Agenda) • Written Agenda Cuts Diagnostic Error by 38%

Primary-care time-motion trials show clinicians interrupt a patient’s opening statement after a median of just 11 seconds (PMID: 29972200), and patients immediately forget 40% to 80% of spoken medical instructions (PMID: 12724490). Here are the 7 evidence-backed questions that transform a rushed 15-minute visit into a clear, safe diagnostic and treatment plan.

Doctors Hub (CPT Volume & Bedside) Conditions Hub (Lab Cutoffs)
7 Min Read • ~1,220 Words Read Study Guide →
FDA Food-Effect Bioavailability Crossover Studies N = 3,150 Crossover PK Subjects

What Does "Take With Food" Really Mean on Your Prescription Bottle? (FDA Pharmacokinetics Explained)

Bottom-Line Trial Result: Bile-Salt Drug Absorption (Rivaroxaban 20 mg): 66% Fasting -> ~100% With 500-kcal Meal • Levothyroxine Fasting Gap: +25% TSH Stability

Does "take with food" mean two crackers, a glass of milk, or a full dinner? Under FDA Food-Effect Bioavailability standards and human pharmacokinetic trials, meal timing can shift a drug’s bloodstream absorption (AUC) by -50% to +300% or slash stomach side effects in half (PMID: 12548010, PMID: 9428832). Here is the exact pill-by-pill decoder.

Rx: Metformin ER Rx: Levothyroxine
7 Min Read • ~1,240 Words Read Study Guide →
FDA 12-Year Analysis of 2,070 Human Bioequivalence Trials N = 2,070 Human Crossover Trials

Generic vs. Brand-Name Medications: The 3.5% Bioequivalence Rule & When Pill Fillers Actually Matter

Bottom-Line Trial Result: Mean Generic vs. Brand Difference: 3.56% AUC & 4.35% Cmax (98% Within <10%) • Narrow Therapeutic Index (NTI) Exceptions Decoded

A pervasive myth claims FDA generic drugs are allowed to vary by "up to 20%" from the brand name. In reality, an FDA study of 2,070 human bioequivalence trials (Davit et al., Annals of Pharmacotherapy, PMID: 19776300) proved the average absorption difference between brand and generic is just 3.5%—equivalent to two batches of the brand pill itself. Here is when generics are identical, and the 3 rare exceptions to ask your pharmacist about.

Medications Hub (NADAC Wholesale Prices) Rx: Bupropion XL
7 Min Read • ~1,260 Words Read Study Guide →
3. All Indexed Clinical Studies (187)

Patient Literacy & FDA Rules — Clinical Trials & Study Reports (187)

Page 1 of 7 • Sorted by Participant Sample Size (N)
Meta-Analysis & Systematic Review N = 6,276

Meta-Analysis: Medication non-adherence and its associated factors among heart failure patients in Africa (N = 6,276)

Approximately two in five heart failure patients in Africa are non-adherent to their medication, with prevalence rates varying significantly by region. This rate is exacerbated by financial, clinical, and therapy-related factors. Concerted multi-faceted interventions are urgently needed across the continent.

Global health research and policy • 2026-10-24 Read Study
Multi-Trial Clinical Evidence Synthesis N = 4,820

7 Questions to Bring to Your Next Doctor Visit (And Why They Work)

Patients who bring a simple written list of 5 to 7 focused questions get clearer answers, leave with fewer medication mix-ups, and feel far more confident about their care plan—without making the appointment run longer.

BMJ Quality & Safety / Patient Education and Counseling • 2026-11-01 Read Study
Meta-Analysis N = 451

Meta-Analysis: Efficacy and safety of cenobamate in the treatment of drug-resistant epilepsy (N = 451)

In summary, this is the first comprehensive meta-analysis to evaluate the efficacy and safety of CNB across pediatric, adult, and combined populations. Although pediatric point estimates were numerically similar to adult estimates, these findings are derived from indirect subgroup comparisons and should be interpreted cautiously.

European journal of clinical pharmacology • 2026-11-04 Read Study
Randomized Controlled Trial PMID 42993341

Randomized Controlled Trial: Testing the EQ-HWB-9 with seven-day versus today recall periods in dementia: variability and recall adherence under health fluctuations

No single recall period appears optimal for all PlwD. Recall period selection should consider individual health fluctuation patterns to improve the performance of HRQoL assessments in dementia.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation • 2026-11-06 Read Study
Randomized Controlled Trial PMID 42992423

Randomized Controlled Trial: Effect of a dietary behaviour change education intervention on iron status and linear growth in children aged 6 to 59 months: a cluster-randomised controlled trial in rural Ethiopia

Community-based DIBE improved linear growth and coincided with reductions in IDA and stunting. Integrating practical nutrition education into routine child health services may improve nutritional outcomes in resource-limited settings.Trial registration: ClinicalTrials.gov:NCT04846062.Registered: 15 April 2021, View at: https://clinicaltri.

Primary health care research & development • 2026-11-06 Read Study
Randomized Controlled Trial PMID 42982936

Randomized Controlled Trial: Resistance training and protein supplementation in patients with incurable gastroesophageal cancer

Resistance training combined with protein supplementation was not feasible during first-line chemotherapy in patients with incurable gastroesophageal cancer due to low accrual and low adherence to protein supplementation.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer • 2026-11-05 Read Study
4. Quick Guide • Never Get Fooled by a Headline Again

How to Read a Clinical Study in 30 Seconds

Read FDA Bioequivalence Guide →
1. Relative Risk (RRR) vs. Absolute Risk (ARR)

If a drug drops heart attack risk from 2.0% to 1.0%, headlines scream “50% Relative Risk Reduction!” The real Absolute Risk Reduction (ARR) is 1.0%—meaning 100 people must take the drug (NNT = 100) to prevent 1 event.

2. Double-Blind RCT vs. Observational Association

Food questionnaires and observational cohorts can only show correlation (often confounded by wealth or exercise). Only a Randomized Controlled Trial (RCT) can prove that a drug or supplement actually caused the outcome.

3. Statistical p-Value vs. Clinical Meaning

In a massive 10,000-person trial, a blood pressure drop of 0.8 mmHg can achieve p < 0.05 (statistically significant) while having zero meaningful benefit in your daily life. Always look at the actual effect size.

4. Surrogate Lab Markers vs. Hard Outcomes

Raising HDL cholesterol or tweaking a single lab biomarker does not automatically prevent strokes or extend lifespan. Prioritize trials that measure hard patient outcomes (survival, remission, sleep latency, or GI tolerability).

Evidence Methodology, PubMed Verification & YMYL Standards

Frequently Asked Questions About dotMD Clinical Trial Breakdowns

Why does dotMD report both Absolute Risk Reduction (ARR) and Relative Risk Reduction (RRR) on clinical trials?

Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.

How does dotMD separate human randomized controlled trials (RCTs) from animal or observational studies?

Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.

Why did dotMD replace synthetic "Study Rigor Scores" with primary PubMed PMIDs and trial metadata?

Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.

How do dotMD Research Breakdowns connect to Conditions, Medications, Supplements, and Specialist Doctors?

Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.